Hyderabad - (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028) Laurus Labs Limited a leading research & development-driven, fully integrated pharmaceutical and biotech company in India signs an agreement with MPP ( Medicine Patient Pool) for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir.

Commenting on the development, Dr.Satyanarayana Chava, Founder and CEO, Laurus Labs said, 'We are happy to sign an agreement to manufacture the oral Covid-19 antirviral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission.'

About Laurus Labs Limited

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs. We also develop and manufacture oral solid formulations, provide contract research and manufacturing services (CRAMS) to Global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals.

We are passionate about advanced chemistry skills. Our proven expertise in bringing innovative solution, manufacturing efficiencies and unwavering quality focus has won us long-standing relationship with our global customers. Laurus employs 4800+ people, including around

750+ scientists at more than 8 facilities approved by major regulatory agencies USFDA, WHO-Geneva, UK-MHRA etc. During FY2021 Laurus generated over ? 4,800 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, Certified Great Place to Work and Rated 'A' by leading MSCI ESG Ratings.

Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit http://www.lauruslabs.com

Contact:

Pavan Kumar N

Laurus Labs Ltd.

Tel: +91 40 6659 4380

Email: mediarelations@lauruslabs.com

(C) 2022 Electronic News Publishing, source ENP Newswire